First human trial begins for potential eye disease pill
NCT ID NCT07417566
Summary
This is the first study in humans to test the safety of an oral tablet called DC6001, which is being developed for Stargardt disease—a genetic eye condition that causes vision loss. The trial will enroll 76 healthy Chinese adults to see how their bodies process different doses of the drug and check for any side effects. Researchers will give participants either the real drug or a placebo (inactive pill) in increasing doses to find the safest amount before testing in patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STARGARDT DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tongren Hospital
RECRUITINGBeijing, Beijing Municipality, 100730, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.